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Abstract
To further investigate into the relapses of Henoch–Schönlein purpura (HSP), we analyzed the frequency, clinical features, and
predictors of relapses in series of 417 unselected patients from a single center. After a median follow-up of 12 (interquartile range
[IQR]: 2–38) years, almost one-third of the 417 patients (n=133; 32%; 85men/48 women) had experienced at least 1 relapse. At
the time of disease diagnosis, patients who later experienced relapses had less commonly infections than those who never
suffered flares (30.8% vs 41.9%; P=0.03). In contrast, patients who experienced relapses had a longer duration of the first
episode of palpable purpura than those without relapses (palpable purpura lasting >7 days; 80.0% vs 68.1%; P=0.04).
Abdominal pain (72.3% vs 62.3%; P=0.03) and joint manifestations (27.8% vs 15.5%; P=0.005) were also more common in
patients who later developed relapses. In contrast, patients who never suffered relapses had a slightly higher frequency of fever at
the time of disease diagnosis (9.3% vs 3.8%; P=0.06). At the time of disease diagnosis, corticosteroids were more frequently
given to patients who later had relapses of the disease (44% vs 32% in nonrelapsing patients; P=0.03). Relapses generally
occurred soon after the first episode of vasculitis. The median time from the diagnosis of HSP to the first relapse was 1 (IQR: 1–2)
month. The median number of relapses was 1 (IQR 1–3). The main clinical features at the time of the relapse were cutaneous
(88.7%), gastrointestinal (27.1%), renal (24.8%), and joint (16.5%) manifestations. After a mean±standard deviation follow-up of
18.9±9.8 years, complete recovery was observed in 110 (82.7%) of the 133 patients who had relapses. Renal sequelae
(persistent renal involvement) was found in 11 (8.3%) of the patients with relapses. The best predictive factors for relapse were
joint and gastrointestinal manifestations at HSP diagnosis (odds ratio [OR]: 2.22; 95% confidence interval [CI]: 1.34–3.69, and
OR: 1.60; 95% CI: 1.01–2.53, respectively). In contrast, a history of previous infection was a protective factor for relapses (OR:
0.60; 95% CI: 0.38–0.94). In conclusion, joint and gastrointestinal manifestations at the time of diagnosis of HSP are predictors of
relapses.
Abbreviations: CI = confidence interval, ESR = erythrocyte sedimentation rate, HSP = Henoch–Schönlein purpura, IQR =
interquartile range, OR = odds ratio, RF = rheumatoid factor, SD = standard deviation.
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Henoch–Schönlein purpura (HSP) is a systemic vasculitis
characterized by the presence of palpable purpura, joint
manifestations, abdominal pain, and nephritis.[1–6] HSP is
typically a childhood disorder that can also occur in adults.[1,7,8]
Whereas in children is usually a self-limited benign disease, in
adults it has been associated with more severe clinical features
and a poorer outcome.[9–11] Nonetheless, the overall prognosis of
the disease is usually good.
Relapses are common in HSP. However, information
specifically focused on relapses is scarce and results are often
discordant. In this regard, the frequency of relapses reported in
previous studies ranges from 2.7% to 51.7%.[12,13] Relapses
present in most cases as a new episode of cutaneous rash that is
often associated with gastrointestinal and renal manifesta-
tions.[12,13] Patient selection due to severity, mainly for the
presence of renal manifestations at the time of diagnosis, may be
one of the main reasons for the discrepancy in the frequency and
clinical spectrum of relapses in HSP. In some cases, the numbers
of patients included in the studies are small. More importantly, in
most series full information on the clinical manifestations of the
vasculitis at the time of the relapses, the median time to relapse
since the diagnosis, and the average number and duration of
relapses is not available. Furthermore, there are series that only
include adults,[12,17] whereas others are exclusively focused on
children.[13–16]
Taking into account these considerations, we aimed to assess
the frequency clinical features and predictors of relapses in a large
series of unselected patients with HSP from a single center.2. Patients and methods
Retrospective study of 417 consecutive patients attended at a
single tertiary care center between January 1975 and December
2012. Patients were diagnosed with HSP according to the criteria
proposed by Michel et al, based on the American College of
Rheumatology (ACR) database and methodology.[19,20] We used
these criteria because we have recently reported that the
European League Against Rheumatism criteria showed low
concordance with previous sets of HSP classification criteria.[21]
HSP was confirmed by a skin biopsy in 110 cases (most of them
adults), showing the typical histological findings of leukocyto-
clastic vasculitis, including neutrophilic infiltration, leukocyto-
clasia, and fibrinoid necrosis into the vessel wall of arterioles,
capillaries, and postcapillary venules, and red cell extravasa-
tion.[22,23] The remaining 307 patients, in whom a skin biopsy
was not performed, had typical nonthrombocytopenic symmetric
palpable purpura. In addition, all of them fulfilled the criteria
proposed by Michel et al.[19]
This is an observational study on patients with HSP with
relapsing disease. In cases like this, according to SpanishNational
Regulation, an Ethical Committee approval is not mandatory.
2.1. Clinical definitions
Classification by age groups: As previously reported,[9,19,20,24,25]
for the purpose of the present study patients older than 20 were
considered adults, and those 20 years of age or younger were
considered children. As previously discussed in former studies of
our group, the cut-off age of 20 was chosen because this age was
proposed as a criterion for HSP by the ACR (age  20 years at
disease onset),[20] and because this age best discriminated HSP
from hypersensitivity vasculitis in the study by Michel et al.[19]2
Precipitating factors: As previously reported when we assessed
the clinical spectrum of HSP in northern Spain,[2] we considered a
drug or a mild infection (in most cases an upper respiratory tract
infection) as the probable precipitating factor(s) for a cutaneous
vasculitis if the drug intake or the onset of the infectious process
started within the week before the development of the vasculitis
cutaneous lesions. Nevertheless, if the cutaneous vasculitis
occurred after antibiotic therapy for a mild infection, both
the infection and the drug were considered as the possible
precipitating factors. Fever was considered to be present if the
temperature was >37.7°C, regardless of the site where the
temperature was assessed and the age of the patient.[2] Joint
manifestations were defined if the patients had arthralgia with or
without joint swelling (arthritis). As described in a former study
of our group, nephropathy was divided in 2 categories: mild and
severe.[25] Mild nephropathy was defined if the patients had
microhematuria (≥5 red cells/high power field) and/or protein-
uria that did not reach the nephrotic range. Severe nephropathy
was considered to be present when the patient had 1 of the
following findings: nephrotic syndrome: defined as plasma
albumin level  25g/L and either 1g of proteinuria/d per m2
of body surface area in children or >3.5g of proteinuria/d in
adults, with or without the presence of edema; or acute nephritic
syndrome that was defined as hematuria with at least 2 of the
following features hypertension, elevated plasma urea or
creatinine serum levels, and oliguria. Renal insufficiency was
defined as creatinine level >125% of the upper limit of normal.
The spectrum of gastrointestinal manifestations encompassed the
presence of at least 1 of the following manifestations: bowel
angina (characterized by the presence of diffuse abdominal pain
that worsened after the meals), gastrointestinal bleeding (if the
patient suffered melena or hematochezia or he/she had a positive
stool Guaiac test), and nausea and vomiting in the context of the
vasculitis. Constitutional symptoms were considered to be
present if the patient had asthenia and/or anorexia and weight
loss of at least 4 kg. A relapse was defined when a patient
previously diagnosed with HSP and asymptomatic for at least 4
weeks, presented again a new flare of cutaneous lesions or other
systemic manifestations of the vasculitis.[2,9]2.2. Laboratory studies
As previously described when we assessed the clinical spectrum of
HSP in northern Spain,[2] we performed full blood cell count,
Westergren erythrocyte sedimentation rate (ESR)/h, and urinaly-
sis in most patients. Also, as previously described,[2] most adults
with HSP were tested for rheumatoid factor (RF) (which was
initially performed by quantitative latex agglutination test, and
later on by nephelometry), antinuclear antibodies (ANAs)
(initially by indirect immunofluorescence initially using rodent
tissues as substrate and more recently by Hep-2 cells), and serum
C3 and C4 complement levels (initially by radial immunodiffu-
sion and more recently by using nephelometry). Other testing
such as antineutrophil cytoplasmic antibodies was determined in
patients seen after 1992. Antineutrophil cytoplasmic antibodies
were initially performed by indirect immunofluorescence on
alcohol fixed neutrophils and later on using ELISA with purified
proteinase-3 and myeloperoxidase.[2] As previously reported,
cryoglobulins as well as the composition of the cryoprecipitate
were assessed by double immunodiffusion with specific anti-
bodies, and immunoglobulins were studied by nephelometry.[2]
Other laboratory tests such as anti-DNA antibodies (by
immunofluorescence using Chrithidia luciliae as a substrate),
Table 1
Main demographic, etiological, and clinical features’ differences
between patients with HSP who experienced further relapses and
those who did not suffer this complication.







Median age (IQR), y 7 (5.0–22.5) 8 (6.0–18.5) 0.18
Sex (men/women), n 85/48 155/129 0.09
Children/adults, n 103/30 212/72 0.62
Etiological factors, %
Infections 30.8 41.9 0.03
URTI 24.1 36.6 0.01
Drug intake 14.3 20.1 0.17
b-Lactam antibiotics 7.5 9.2 0.71
Clinical features, %
Fever 3.8 9.3 0.06
Typical palpable purpura 97.0 99.6 0.04
Lasting >7 d 80.0 68.1 0.04
Gastrointestinal involvement 72.3 62.3 0.04
Abdominal pain 72.2 60.9 0.03
Nausea and/or vomiting 15.8 13.7 0.65
Melena and/or rectorrhagia 15.0 12.0 0.43
Joint manifestations 27.8 15.5 0.005




Severe† 5.3 7.7 0.41
Nephrotic syndrome 3.0 5.6 0.33
Nephritic syndrome 3.0 2.8 0.99
Renal insufficiency‡ 1.7 3.1 0.81
HSP = Henoch–Schönlein purpura, IQR = interquartile range, URTI=upper respiratory tract infection.
∗
Microhematuria (≥5 red cell/high power field) and/or proteinuria that did not reach the nephrotic
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hepatitis C, orHIV infection serology, were only performedwhen
considered by the physician who was in charge of the patient.[2]
Anemia was defined if the hemoglobin level was 11g/dL and
leukocytosis if the white blood cell count was ≥11,000/mm3. An
ESR was defined as elevated if it was higher than 20 or 25mm/h
for men or women, respectively.[9,26] IgA levels were considered
to be increased if the total serum IgA level was >400mg/dL.
To reduce the risk of selection bias, in the present study we
included all the patients from our area that fulfilled definitions for
HSP, regardless of whether a biopsy was performed or not. In this
regard, a skin biopsy was carried out in most adults with skin
lesions whereas it was only done in a small number of children.[2]
Biopsies were not generally performed to children with typical
HSP vasculitis who did not suffer severe renal involvement.[2] We
feel that the inclusion of children with typical HSP without tissue
biopsy would reduce the risk of selection bias providing more
accurate information on the actual clinical spectrum of this
vasculitis.[2] A renal biopsy was usually done whenever that a
feature suggestive of severe renal disease, such as protein
excretion above 1g/d or elevated plasma creatinine concentra-
tion, was present. Light microscopy often disclosed mesangial
hypercellularity as well as increased deposition of extracellular
matrix proteins in patients with nephropathy. The typical finding
in these patients was the presence of prominent granular IgA
deposits in the mesangium seen by immunoflourescence.
The duration of the follow-up, time from the diagnosis of HSP
to the first relapse, number of relapses, clinical features at the time
of relapses, treatment, and outcome were recorded in all the
patients.range.
† Nephrotic syndrome or nephritic syndrome.
‡ Serum creatinine levels >125% of the upper normal limit.2.3. Data collection and statistical analysis
Data were first reviewed in an attempt to retrieve the following
information: precipitating factors; clinical, laboratory, and
histopathological features; treatment; and prognosis. These data
were extracted from the clinical records according to a specific
protocol, reviewed for confirmation of the diagnosis, and stored
in a computerized database. To minimize entry error all the data
were double checked.
Besides chart review,mostpatientswere interviewedbyphone to
know if relapses had occurred after the last visit at the hospital. The
statistical analysis was performed with the STATISTICA software
package (Statsoft Inc., Tulsa, OK). All continuous variables were
tested for normality. Results were expressed as mean± standard
deviation (SD) or asmedian and range or interquartile range (IQR)
as appropriate. Student t test orMann–WhitneyU test was used to
compare continuous variables, andx2 test for categorical variables.
Univariate and then multivariate stepwise logistic regression
analyses were conducted to identify the independent predictors of
HSP relapse. A P value<0.05 was considered statistically
significant in all the calculations.3. Results
We included 417 patients diagnosed with HSP. After a median
follow-up of 12 (IQR: 2–38) years almost one-third of them (n=
133; 32%; 85men/48 women) had experienced at least 1 relapse.
One hundred three of 133 patients with relapses were children or
young adults (age 20 years).
The main demographic, clinical, and laboratory findings of the
patients with relapsing and nonrelapsing HSP are summarized in
Tables 1 and 2.3
3.1. Demographic, etiologic, and clinical differences at the
time of disease diagnosis between patients with and
without relapses
No differences according to gender or age at the time of disease
diagnosis between patients with HSP who had relapses and those
who did not experience this complication were found. Neverthe-
less, several clinical differences between these 2 groups were
observed. With regard to potential precipitating factors for the
development of the disease, infections, in particular upper
respiratory tract infections, were less commonly observed in the
subgroup of patients who later suffered relapses (30.8% vs
41.9% in those without relapses; P=0.03). However, acute otitis
media and mumps were more commonly observed in the
subgroup of patients who experienced relapses (2.26% vs
0.35% and 0.75% vs 0.35%, respectively) but the difference
did not achieve statistical significance. Other infections were
uncommon in both groups. On the other hand, the frequency of
drug intake shortly before the onset of the disease was similar in
both groups (Table 1).
With respect to differences in the clinical spectrum of the
disease at the time of disease diagnosis between those who over
the extended follow-up developed relapses and those who did not
have this complication, patients who experienced relapses had a
longer duration of the first episode of palpable purpura than
those without relapses (palpable purpura lasting>7 days; 80.0%
vs 68.1%; P=0.04). It was also the case for abdominal pain
(72.3% vs 62.3%; P=0.03) and joint manifestations (27.8% vs
15.5%; P=0.005). In contrast, patients who never suffered
Table 2
Laboratory findings and treatment differences between patients
with HSP who experienced further relapses and those who did not
suffer this complication.
Parameters and treatment at










Hemoglobin levels, g/dL 13.2±1.8 12.1±1.9 0.01
Anemia†, % 3.8 8.8 0.07
Increased ESR‡, % 73.9 (34/46) 83.5 (71/85) 0.25
Increased serum IgA levelsx, % 26.9 (7/26) 35.1 (13/37) 0.59
Positive rheumatoid factor, % 7.7 (4/52) 3.6 (4/110) 0.27
Positive antinuclear antibodies, % 27.3 (15/55) 8.3 (10/121) 0.002
Low C3 and/or C4, % 6.6 (5/76) 8.6 (12/139) 0.79
Treatment
NSAIDs, % 15.0 13.7 0.76
Corticosteroids, % 43.6 32.0 0.03
Cytotoxic drugs, % 7.5 4.2 0.16
Values are percentages (no. of positive/total no. of tested).
ESR = erythrocyte sedimentation rate, HSP = Henoch–Schönlein purpura, NSAIDs=nonsteroidal




‡≥ 20 or 25mm/h for men or women, respectively.
x Serum IgA level >400mg/dL.
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disease diagnosis (9.3%) than those with relapses (3.8%); P=
0.06. No significant differences in the frequency of nephritis and
renal insufficiency were seen between both groups of patients
(Table 1).3.2. Differences in the laboratory data found at the time
of diagnosis of the disease between HSP patients with
and without relapses
A raised ESR was frequently seen at the time of disease diagnosis.
Nevertheless, no significant differences were seen between the
group of patients who experienced relapses and those who never
had flares of the disease (Table 2).
Relapsing patients had significantly lower white blood count
(mean value: 13,585 leukocytes/mm3) and higher hemoglobin
(mean value: 13.2g/dL) than those who did not suffer flares
(mean values 15,260 leukocytes/mm3 and 12.1g/dL, respectively)
(Table 2). ANA positivity was more commonly disclosed in the
relapsed group (27.3% vs 8.3%; P=0.002). Nevertheless, none
of the patients with positive ANA met classification criteria for
systemic lupus erythematosus. There were no significant differ-
ences in the frequency of RF. It was also the case for IgA elevation
or lower levels of serum complement (Table 2).3.3. Treatment and outcome
Corticosteroids were the drugs more commonly used in both the
patients with and those without relapses of the disease.
Nevertheless, they were more frequently given to patients who
later had relapses (44% vs 32 % in nonrelapsing patients; P=
0.03). At the time of the disease diagnosis, the median initial
corticosteroid dose in the subgroup who later experienced
relapses was 30 (IQR: 20–45) mg whereas in those who never
suffered relapses it was 30 (IQR 30–45) mg (P=0.6). The
duration of corticosteroids at the time of disease diagnosis in the4
subgroup of patients with HSP who later had relapses was 1
(0.5–3) month versus 1.5 (0.7–4) months in those who never
suffered relapses (P=0.9). At that time, corticosteroids were
prescribed because of persistence of skin lesions or visceral
involvement, including severe abdominal pain, gastrointestinal
bleeding, or nephropathy. Cytotoxic immunosuppressive drugs
were given usually either as corticosteroid-sparing agents or as
add-on therapy in patients with severe renal involvement.
However, no differences in the use of immunosuppressive drugs
between both groups were seen (Table 2). In this regard, 10 of the
133 who experienced relapses were treated with immunosup-
pressive drugs at the time of disease diagnosis (azathioprine 5,
oral cyclophosphamide 3, and mycophenolate 2). Twelve of the
284 who did not have relapses were also treated with
immunosuppressive drugs (azathioprine 5, oral cyclophospha-
mide 6, and oral methotrexate 1; P=0.16).
After a mean±SD follow-up of 18.9±9.8 years, complete
recovery was observed in 110 (82.7%) of the 133 patients who
had relapses. Renal sequelae (persistent renal involvement) was
found in 11 (8.3%) of the patients who suffered relapses. In most
cases, renal damage was of mild severity, not associated with
impairment of renal function and manifested by hematuria or
hematuria plus proteinuria. At last follow-up chronic renal
insufficiency was only observed in 2 (1.5%) patients from the
group with relapses. During the first episode of the vasculitis (at
time of diagnosis) and then throughout the course of the disease,
including the extended follow-up, dialysis was only required in 2
patients from the group with relapses.
Out of 5 patients with relapses, 1 received medication at the
time of a flare of the disease. As occurred at the time of disease
diagnosis, corticosteroids were the drugs more commonly given
in the episodes of relapses (17%). Other drugs used at that time
were immunosuppressive drugs (3%) and nonsteroidal anti-
inflammatory drugs (3%).3.4. Frequency, clinical features, and predictive factors
of relapses
Relapses generally occurred soon after the first episode of
vasculitis. In this regard, the median time from the diagnosis of
HSP to the first relapse was 1 (IQR: 1–2) month. The median
number of relapses was 1 (IQR: 1–3). In general, the duration of
the vasculitis at the time of the relapses was shorter than at the
time of the disease diagnosis (median duration of the vasculitic
episodes of relapses 3.5 [IQR: 3–5] days).
As shown in Fig. 1, cutaneous involvement in almost 90% of
patients (in the majority of the cases presenting as typical
palpable purpura), either isolated or in combination with other
clinical manifestations, was themost common feature observed at
the time of the relapses of the disease. Other clinical
manifestations observed at the time of the relapses in this
subgroup of 133 patients with HSP were gastrointestinal
(27.1%), renal (24.8%), and joint (16.5%) manifestations.
Regarding gastrointestinal manifestations at the time of the
relapses, abdominal pain was the manifestation observed in most
patients followed by nausea and/or vomiting. Melena and/or
rectorrhagia only occurred in a few patients at the time of the
relapses.
A regression model for the risk of relapses in HSP is shown in
Table 3. The multivariate analysis disclosed that the best
predictors of relapses were joint (odds ratio [OR]: 2.22; 95%
confidence interval [CI]: 1.34–3.69; P=0.002) and gastrointesti-




















Figure 1. Clinical spectrum at the time of the relapses in 133 patients with Henoch–Schönlein purpura who experienced flares after the diagnosis of disease. Data
are expressed as percentages. C = cutaneous lesions, GI = gastrointestinal involvement, J = joint involvement, N = nephropathy.
Calvo-Río et al. Medicine (2016) 95:28 www.md-journal.comthe time of diagnosis of HSP. In contrast, a history of previous
infection at the time of disease diagnosis was found to be a
protective factor against relapses of HSP (OR: 0.60; 95% CI:
0.38–0.94; P=0.02).
In a further step, to determine if there were potential differences
in what predicts relapses between children and adults, we
performed a multivariable logistic regression analysis in each ageTable 3
Regression models for the risk of relapses in patients with HSP
from northern Spain.
Variable OR (95% CI) P
Univariate analysis
Sex (men) 1.47 (0.96–2.25) 0.07
Age <20 y (yes) 1.17 (0.72–1.90) 0.54
Previous infection (yes) 0.62 (0.40–0.96) 0.03
Upper respiratory tract infection (yes) 0.55 (0.34–0.87) 0.01
Known etiologic factor (yes) 0.67 (0.44–1.03) 0.07
Previous drug intake (yes) 0.66 (0.38–1.17) 0.16
Previous b-lactam antibiotic (yes) 0.81 (0.38–1.73) 0.58




Renal involvement at diagnosis (yes) 1.10 (0.73–1.67) 0.65
Purpura lasting for >7 d at diagnosis (yes) 1.87 (1.04–3.38) 0.04
Anemia at diagnosis (yes) 0.41 (0.15–1.08) 0.07
Leukocytosis at diagnosis (yes) 0.65 (0.41–1.04) 0.07
Elevated ESR at diagnosis (yes) 0.55 (0.23–1.34) 0.19
Elevated IgA at diagnosis (yes) 0.68 (0.23–2.04) 0.49
Pharmacological treatment (yes) 1.57 (1.03–2.37) 0.04
Corticosteroid use during the first
HSP episode (yes)
1.64 (1.07–2.51) 0.02




Joint manifestations at HSP diagnosis (yes) 2.22 (1.34–3.69) 0.002
Gastrointestinal manifestations at HSP
diagnosis (yes)
1.60 (1.01–2.53) 0.04
Previous infection (yes) 0.60 (0.38–0.94) 0.02
CI = confidence interval, ESR = erythrocyte sedimentation rate, HSP=Henoch–Schönlein purpura,
OR = odds ratio.
5
subgroup of patients with HSP (children and adults). In children
(age  20 years at disease onset), a history of infection shortly
before the onset of HSP manifestations was associated with a
lower risk of relapses (OR: 0.57; 95% CI: 0.35–0.93; P=0.025).
In contrast, the presence of joint manifestations at the time of
disease diagnosis was the best predictor of relapses of HSP in
children (OR: 2.51; 95% CI: 1.42–4.44; P=0.002). In adults,
however, the presence of gastrointestinal manifestations at the
time of disease diagnosis was the best predictor of relapses of HSP
(OR: 4.00; 95% CI: 1.38–11.62; P=0.011).
Finally, as shown in Table 3, the use of corticosteroids during
the first HSP episode was associated with an increased risk of
relapses of HSP (OR: 1.64; 95% CI: 1.07–2.51; P=0.02).
However, the association of corticosteroid use with relapses of
the disease was only statistically significant in the subgroup of
children with HSP (OR: 2.25; 95% CI: 1.34–3.77; P=0.002).
4. Discussion
HSP is considered a benign and self-limited disorder, being renal
involvement the most severe complication.[1–6] Many reports
have assessed the frequency of nephropathy in HSP,[1,2,6,9,27]
and some of them have tried to identify predictive factors for
renal involvement.[17,28–30] However, relapses, a well-known
complication of HSP,[2] have been scarcely assessed.[12–16]
Moreover, studies dealing with relapses were focused mainly on
patients with renal involvement, included a relatively small
number of cases or were performed in pediatric or adult
populations separately (Table 4).[12–18] Therefore, the frequen-
cy, type, and predictive factors for HSP relapses are not well
established.
Our study encompassed a large and unselected series of 417
patients with HSP seen in a single tertiary care center during a 37-
year period. The main features of our patients are similar to those
from other series published in the literature.[10,31–34]
The frequency of patients with HSP who experience relapses
varies greatly from a series to another. It ranges from 2.7% to
51.7% (Table 4).[12–18] This is probably due to the wide
differences in the selection of patients in the different studies. In
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6
Clinical manifestations during relapses have shown great
variability in the different studies. Nevertheless, the most
common feature is the presence of cutaneous lesions, either
isolated or in combination with gastrointestinal or renal
involvement (Table 4). As shown in our series, the relapsing
episode usually tends to mimic the initial one.[13,14]
In our series, we have identified 3 independent predictive
factors for HSP relapses; joint and gastrointestinal manifestations
at and a history of previous infection at the time of the diagnosis
of HSP. Interestingly when patients were stratified according to
the age of disease onset in children (age 20 years or younger) and
adults, we observed that relapses in children occurred more
commonly in those presenting with joint manifestations whereas
in adults the relapses of the disease were more commonly seen in
those patients who experienced gastrointestinal manifestations at
the time of disease diagnosis. In addition, the protective role of
infection against the risk of relapses in HSP was mainly related to
children with HSP.
In keeping with Trapani et al,[35] we also observed an
association between the use of corticosteroids at the time of
disease diagnosis and the risk of relapses. However, this
association was only observed in children but not in adults with
HSP. Table 4 shows the factors associated with HSP relapses in
other published series. Thus, Shin et al[15] reported severe bowel
angina, age >10 years, persistent purpura (>1 month), and
leukocytosis as the best set of predictors for relapse. Byun et al[12]
described age > 30 years, the presence of an underlying disease,
persistent purpura (>1month), abdominal pain, and the presence
of hematuria as the predictors of relapsing HSP. Moreover, there
are other studies in which only a predictive factor, such as
persistent purpura[16] or late onset of HSP,[14] was found. In this
regard, Calviño et al[18] observed that children who experienced
renal sequelae were at greater risk relapses than those patients
without renal impairment.
The good renal prognosis observed in our cohort might be at
odds with other reports of long-term risk of renal insufficiency
among patients diagnosed with HSP. This fact was previously
highlighted when we described the clinical spectrum of HSP in
northern Spain.[2] In this regard, there is a great variability in
clinical features and outcome in different series. It may be related
to several factors including selection bias because some studies
are mainly based on patients with nephritis.[36] On the other
hand, the use of variable criteria for the classification of HSP
among different series may be another factor to explain
differences in the renal outcome. Another factor that may
explain differences in the renal outcome is the absence of a
standardized therapeutic management, especially in cases of
nephropathy. In our study, we assessed a large series of
unselected patients with HSP. In this regard, to avoid selection
bias, we included all patients seen in the different departments
attending patients with HSP in our hospital (Rheumatology,
Pediatrics, Nephrology, Dermatology and Internal Medicine).
Therefore, we included not only cases presenting with severe
disease or with atypical presentation but also cases with mild
disease. Moreover, in our study, we included patients of all ages,
adults and children. However, it is known that the frequency of
nephritis and the risk of renal insufficiency are more common in
adults.[1,9,10,36]
The pathogenesis of relapses in HSP still remains unknown.
Therefore, it would be desirable to search for novel biomarkers
that could predict relapses more accurately. In this sense, several
studies have revealed the relevant role of some genetic
variants (including those located in the human leukocyte antigen
[9] Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, et al.
Calvo-Río et al. Medicine (2016) 95:28 www.md-journal.com[HLA] system) in both, HSP susceptibility and clinical
heterogeneity.[37–40] However, a minority of studies are focused
on the predisposition to relapse. Thus, HLA B35 haplotype has
been related to relapsing HSP.[41] Noteworthy, we have found
that an infection shortly before the onset of the vasculitis, which is
a predisposing factor for the first episode of HSP is, by contrast, a
protective factor for a relapsing disease. The reason for this
finding is unknown. It is possible that factors associated with
infection in HSP could be of transient nature and, thus, lead to a
more limited, nonrelapsing disease. On the other hand, it is
possible that patients fulfilling definitions for HSP in whom an
infection, in particular an upper respiratory tract infection, was
closely related to or associated with the onset of the disease may
represent a different subset of this vasculitis, different from that
unrelated to infection. In this regard, abnormal autoimmune tests
(RF and ANAs) were more frequently observed in patients with
HSP who experienced relapses than in those who never had flares
of the disease.
Finally, given the nature of this retrospective cohort, changing
techniques used for assays is an understandable consequence.
However, we acknowledge this as a potential limitation of the
study.
In conclusion, we have assessed the frequency, type, and risk
factors of relapses in a large series of unselected patients withHSP
from a single center. They occur in almost one-third of the
patients and the clinical features at the time of the relapses are
similar to those found at disease diagnosis. We should pay special
attention to those patients presenting with joint or gastrointesti-
nal manifestations at the time of diagnosis of HSP, because the
relapsing rate seems to be higher in these cases. In contrast, an
infection shortly before the onset of HSP appears to be a
protective factor for relapsing disease. Further population-based
studies including large series of patients are needed to confirm our
data and identify other possible factors that allow us to predict
more accurately relapses in patients with HSP.Acknowledgment
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